Vaccines Market Research Reports & Industry Analysis

Vaccine stands for a preparation of dead, attenuate or else modified viruses, bacteria and other microorganisms utilized as an inoculation to immunize against any disease by way of stimulating antibodies’ production. With constant technology upgrades and launches of new medicinal products, Vaccines proved to be the most sophisticated healthcare aid ever created in the pharma’s history.

The global Vaccine Industry is thriving mainly owing to the chronic availability of different diseases, both already-existing and cropping up on the horizon, which can be luckily prevented with Vaccines’ assistance. Pediatric Vaccines form the largest and the most hastily evolving segment as against adult Vaccines, with the trend predicted to stay unaltered in the impending period. The worldwide Vaccine Market is primarily in the paws of such behemoths as Merck & Company, Inc.; Novartis, Pfizer, Inc.; GlaxoSmithKline plc; and Sanofi Pasteur.

The research reports under this Catalogue provide in-depth assessments of the global Vaccine Industry, discussing pressing market issues and statistical figures. The research reports cover the sizing (value/volume) and short-to-long-run forecasts for the overall Vaccine Market and its major segments, and for numerous geographic markets. The listing of M&As among the Vaccine universe participants with new products’ reviews, alongside company profile information can be derived from the research reports too.

Found 422 publications
Ebola Virus Vaccine Market & Pipeline Insight US$ 1,500.00

... has been met till now. The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, ... return on investment. “Ebola Virus Vaccine Market & Pipeline Insight” Report Highlight: Ebola Virus Infection Market Overview Ebola Vaccine Clinical Trial ...

Oct, 2014 80 pages
Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins US$ 255.00

Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins The present Competitive Intelligence Report about prophylaxis and therapy of Rabies ... virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

Sep, 2014 33 pages
Competitor Analysis: Ebola Virus Vaccines and Therapeutics US$ 255.00

Competitor Analysis: Ebola Virus Vaccines and Therapeutics The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections ... Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

Oct, 2014 43 pages
Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020 US$ 2,625.00

... drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD). ... held in past years concerning the development of ebola viral disease therapeutics Pin-point analysis of geographic segments helps to identify opportunities for ...

Sep, 2014 55 pages
Global Cancer Vaccines Market & Pipeline Analysis US$ 2,400.00

... present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into ... Pipeline by Phase, Indication, Company & Country Global Cancer Vaccine Clinical Pipeline: 289 Vaccines Marketed Cancer Vaccines: 12 Vaccines Regulatory Framework for ...

Sep, 2014 864 pages
Global Hepatitis B Vaccines Market 2014-2018 US$ 2,500.00

... transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person ... the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the ...

Aug, 2014 91 pages
Global Meningococcal Vaccines Market 2014-2018 US$ 2,500.00

... to grow at a CAGR of 15.00 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the ... caused by different serogroups of Neisseria meningitides. TechNavio's report, the Global Meningococcal Vaccines Market 2014-2018, has been prepared based on an in-depth ...

Aug, 2014 78 pages
OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 US$ 7,995.00

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 SUMMARY Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded ... 2015-2020. Annual cost of therapy (ACOT) and major pipeline vaccine sales in this forecast period are included. Key topics covered ...

Jul, 2014 188 pages
2014 Market Research Report on Global Encephalitis Vaccine Industry US$ 2,850.00

2014 Market Research Report on Global Encephalitis Vaccine Industry was a professional and depth research report on Global Encephalitis Vaccine industry that you ... from Encephalitis Vaccine industry chain related technical experts and marketing experts during Research Team survey and interviews. The report ...

Jun, 2014 176 pages
V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against human ... Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV ...

Mar, 2014 69 pages
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against ... sector. In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more ...

Mar, 2014 94 pages
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against ... SWOT analysis. Sales forecast for the top drugs in the Japan from 2012-2022. Analysis of the impact of key events as well the drivers ...

Mar, 2014 86 pages
PharmaPoint: Prophylactic Human PapillomaVirus Vaccines - Current and Future Players US$ 2,995.00

... SUMMARY GlobalData has released its pharma report, “PharmaPoint: Prophylactic Human PapillomaVirus Vaccines - Current and Future Players”. The report is a vital ... key companies shaping and driving the global Prophylactic Human Papillomavirus Vaccines market. The report provides insight into the competitive ...

Mar, 2014 40 pages
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against ... as a SWOT analysis. Sales forecast for the top drugs in the Canada from 2012-2022. Analysis of the impact of key events as well the ...

Mar, 2014 94 pages
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against ... program from 2013 will drive the expansion of the HPV vaccines market over the forecast period. GlobalData expects that following ...

Mar, 2014 91 pages
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 US$ 6,995.00

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization ... other countries Spain has relatively high coverage rates for HPV vaccination, which GlobalData expects will persist throughout the forecast period ...

Mar, 2014 127 pages
Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against human ... as a SWOT analysis. Sales forecast for Gardasil for the top nine countries from 2012 to 2022. Sales information covered for the US, France, ...

Mar, 2014 45 pages
Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 SUMMARY The first prophylactic vaccine for immunization against human ... as a SWOT analysis. Sales forecast for Cervarix for the top nine countries from 2012 to 2022. Sales information covered for the US, France, ...

Mar, 2014 44 pages
Human Papillomavirus Infections Vaccine Pipeline Analysis US$ 1,800.00

... could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both ... to treat it, either through drugs or through vaccines. “Human Papillomavirus Infections Vaccine Pipeline Analysis” Report Highlights: Human Papillomavirus Vaccine Market Overview ...

Jun, 2014 197 pages
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022 US$ 10,995.00

... The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now ... access. Identify opportunities for the development and delivery of HPV vaccines, and to identify emerging players with potentially strong product portfolios. ...

Mar, 2014 188 pages
Global Vaccine Market Outlook 2020 US$ 1,500.00

... activities and generic competition for off patent products. On the contrary, vaccine segment has developed as highly profitable because of advancements in genomics and ... sales, which thereby allure the market players. The report, “Global Vaccine Market Outlook 2020” provides an extensive research and in-depth ...

May, 2014 135 pages
Global Influenza (Flu) Vaccine Market: Trends & Opportunities (2014-19) US$ 800.00

Scope of the Report The report titled “Global Influenza (Flu) Vaccine Market: Trends and Opportunities (2014-2019)” provides an insight into the ... Abbott Laboratories, Novartis, CSL and Glaxo Smith Kline. Geographical Coverage Global United States Japan Germany United Kingdom Company Coverage Sanofi ...

Apr, 2014 60 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players US$ 2,995.00

Summary GlobalData has released its pharma report, “PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players”. The report is a vital ... with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the ...

Jan, 2014 70 pages
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges US$ 3,900.00 US$ 3,510.00

... , including recent activities of major pharmaceutical companies, insight into the challenges being faced by companies developing therapeutic vaccines and recommendations on clinical development strategies to overcome these potential obstacles and hurdles The report assesses the evolving competitive vaccines ...

Feb, 2014 60 pages
Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 67 pages
Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion ...

Jan, 2014 68 pages
Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 65 pages
Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is ... well as a SWOT analysis. Sales forecast for Infanrix Hexa for top six countries from 2012 to 2022. Sales information covered for the US, ...

Jan, 2014 65 pages
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are ...

Jan, 2014 66 pages
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 91 pages
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 64 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 136 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for the top drugs in Japan from 2012-2022. Analysis of the impact of key events as well the drivers ...

Jan, 2014 89 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for the top drugs in Canada from 2012-2022. Analysis of the impact of key events as well the drivers ...

Jan, 2014 129 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 US$ 6,995.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 191 pages
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for Engerix-B for top seven countries from 2012 to 2022. Sales information covered for the US, Canada, France, ...

Jan, 2014 67 pages
Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for Comvax for the US from 2012 to 2022. Sales information covered for the US Reasons to buy Understand and ...

Jan, 2014 64 pages
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... and chronic infections caused by all known strains of HBV. In 1988, Bimmugen became the first HBV vaccine available in Japan. The antigen ...

Jan, 2014 61 pages
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 64 pages
Global Therapeutic Vaccines Market 2014-2018 US$ 2,500.00

... market. TechNavio's report, the Global Therapeutic Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry ... The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Agenus Inc. ...

Mar, 2014 54 pages
Market Research Report on Global and Chinese Vaccine linkage production line Industry, 2009-2019 US$ 2,400.00

... linkage production line Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Vaccine linkage production line industry. The ... of each company; The breakdown data of Vaccine linkage production line market are presented by company, by country, and by application; The report also ...

Mar, 2014 150 pages
Market Research Report on Global and Chinese Influenza Vaccine Industry, 2009-2019 US$ 2,400.00

... Chinese Influenza Vaccine Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Influenza Vaccine industry. The report ... economic parameters of each company; The breakdown data of Influenza Vaccine market are presented by company, by country, and by application; The report also ...

Feb, 2014 150 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 US$ 10,995.00

... , in particular pediatric combination vaccines and novel adult vaccines, are anticipated to dramatically influence market growth. Scope Overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. ...

Jan, 2014 303 pages
Vaccine Deals and Alliances of 2013 US$ 1,495.00

The Vaccine Deals and Alliances of 2013 provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the ...

Aug, 2014 200 pages
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis US$ 2,000.00

... when purchasing Hard Copy License depending on the location. Ever since HIV was identified as the cause for AIDS 30 years ago, the ... a high probability of succeeding, instead of those which are less promising. “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights: Introduction ...

Mar, 2014 330 pages
Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis, April 2013 US$ 2,499.00

... are the other players in the top five players list. Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the industry and presents its findings in Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis. North ...

Apr, 2013 168 pages
PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update US$ 10,995.00

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update Summary Seasonal Influenza is a respiratory infection ... to gain a competitive advantage. Track drug sales in the global seasonal influenza vaccine market from 2012-2022. Organize your sales and ...

Sep, 2013 332 pages
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update US$ 10,995.00

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update Summary Meningococcal disease is an acute infection caused ... for each age segment and country? Which meningococcal vaccines will face adoption challenges in the market? What is the projected uptake ...

Aug, 2013 316 pages
US Cancer Vaccine Market Outlook 2018 US$ 1,200.00

... charges are applied when purchasing Hard Copy License depending on the location. Cancer vaccines are a viable option for treating many types ... to a combined share of 50% accounted for by Europe and other regions. “US Cancer Vaccine Market Outlook 2018” research study by KuicK Research gives comprehensive ...

Feb, 2014 142 pages
Global Vaccine Market Pipeline Analysis US$ 1,500.00

... sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the ... market is expected to surpass estimated USD 100 billion by 2025. “Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...

Jan, 2014 1150 pages
1 2 3 4 5 >
Skip to top